Publications by authors named "R W Hanf"
Article Synopsis
- A study investigated the effectiveness of elafibranor, a medication for patients with primary biliary cholangitis (PBC) who didn't respond adequately to ursodeoxycholic acid treatment.
- In a 12-week trial with 45 participants, those taking elafibranor saw significant reductions in alkaline phosphatase (ALP) levels compared to a placebo group, with notable decreases in liver disease markers.
- The results indicated elafibranor was safe, well tolerated, and improved various markers of PBC, providing hope for better management of the condition.
Background: Non-invasive tests that can identify patients with non-alcoholic steatohepatitis (NASH) at higher risk of disease progression are lacking. We report the development and validation of a blood-based diagnostic test to non-invasively rule in and rule out at-risk NASH (defined as non-alcoholic fatty liver disease [NAFLD] activity score [NAS] ≥4 and fibrosis stage ≥2).
Methods: In this prospective derivation and global validation study, blood samples, clinical data, and liver biopsy results from three independent cohorts with suspected NAFLD were used to develop and validate a non-invasive blood-based diagnostic test, called NIS4.
Objective: Bile acids (BAs) are signaling molecules controlling lipid and glucose metabolism. Since BA alterations are associated with obesity and insulin resistance, plasma BAs have been considered candidates to predict type 2 diabetes (T2D) risk. We aimed to determine (1) the association of BAs with glucose homeostasis parameters and (2) their predictive association with the risk of conversion from prediabetes to new-onset diabetes (NOD) in a prospective cohort study.
View Article and Find Full Text PDFArticle Synopsis
- Elafibranor, an agonist for specific receptors, was tested for its safety and effectiveness in treating patients with nonalcoholic steatohepatitis (NASH) in a randomized, double-blind, placebo-controlled trial.
- The study involved 276 participants assigned to receive either 80 mg or 120 mg of elafibranor daily for 52 weeks, with evaluations occurring every two months and liver biopsies taken afterward.
- Results indicated that while there was no significant difference in the primary outcome between elafibranor and placebo groups, a higher percentage of patients in the 120 mg group experienced resolution of NASH without worsening fibrosis compared to the placebo group (19% vs. 12%, P
Article Synopsis
- GFT505 is a novel medication targeting liver receptors that showed effectiveness in reducing blood sugar levels and improving insulin sensitivity in diabetic mice.
- Unlike traditional diabetes medications like rosiglitazone, GFT505 did not cause any negative effects on heart health after long-term use in monkeys.
- Overall, GFT505 has a better safety profile and effectively addresses various aspects of type 2 diabetes without the cardiac side effects seen with other treatments.